Wild-Type RAS: Keeping Mutant RAS in CHK

Slides:



Advertisements
Similar presentations
Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.
Advertisements

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell
Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr
Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni
Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells Nilay Sethi, Xudong Dai, Christopher.
Eph-Ephrin Bidirectional Signaling in Physiology and Disease Elena B. Pasquale Cell Volume 133, Issue 1, Pages (April 2008) DOI: /j.cell
Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib Ling Li, Lisheng Wang, Liang Li, Zhiqiang.
Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.
The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.
Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.
CDK Inhibitors: Cell Cycle Regulators and Beyond Arnaud Besson, Steven F. Dowdy, James M. Roberts Developmental Cell Volume 14, Issue 2, Pages
Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung Zvi Granot, Erik Henke, Elizabeth A. Comen, Tari A. King, Larry Norton, Robert Benezra.
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.
A Conditional Mouse Model of Synovial Sarcoma: Insights into a Myogenic Origin Malay Haldar, Jeffrey D. Hancock, Cheryl M. Coffin, Stephen L. Lessnick,
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Taking the Stress out of Melanoma
Volume 1, Issue 1, Pages (June 2007)
Daniel R. Croft, Michael F. Olson  Cancer Cell 
Nomeda Girnius, Roger J. Davis  Cancer Cell 
IRS-1: Auditing the effectiveness of mTOR inhibitors
Mutant p53 gain of function: The NF-Y connection
Volume 14, Issue 2, Pages (August 2008)
Volume 11, Issue 4, Pages (April 2007)
The Akt-mTOR tango and its relevance to cancer
RAS unplugged: Negative feedback and oncogene-induced senescence
Revealing the genomic heterogeneity of melanoma
Kinase inhibitors: Vice becomes virtue
CALming Down T Cell Acute Leukemia
George-Lucian Moldovan, Alan D. D'Andrea  Cancer Cell 
Annapoorni Rangarajan, Sue J. Hong, Annie Gifford, Robert A. Weinberg 
DAISY: Picking Synthetic Lethals from Cancer Genomes
mTORC1: Turning Off Is Just as Important as Turning On
Suppressing NFAT Increases VEGF Signaling in Hemangiomas
Kidney Cancer: Now Available in a New Flavor
Volume 13, Issue 1, Pages 1-2 (January 2008)
A Radical Role for p38 MAPK in Tumor Initiation
CALming Down T Cell Acute Leukemia
PICS-ure This: Prosenescence Therapy?
A Zygotic Checkpoint for Unrepaired Lesions
Volume 46, Issue 5, Pages (June 2012)
Raf-1 and Squamous Cell Carcinoma: Rok-ing the Boat
IRS-1: Auditing the effectiveness of mTOR inhibitors
The Not-so-Skinny on Muscle Cancer
NOTCH and PI3K-AKT Pathways Intertwined
Breaking News on Fragile Sites in Cancer
Hard Times for Oncogenic BRAF-Expressing Melanoma Cells
Brother’s Keeper: Wild-Type Mutant K-Ras Dimers Limit Oncogenesis
DUB-le Trouble for Cell Survival
Volume 14, Issue 4, Pages (October 2008)
Tailor Made Protein Synthesis for HSCs
To Infinium, and Beyond! Cancer Cell
Volume 10, Issue 3, Pages (September 2006)
All Roads Lead to the Ribosome
ATMIN: A New Tumor Suppressor in Developing B Cells
c-Raf in KRas Mutant Cancers: A Moving Target
Cancer: The Transforming Power of Cell Competition
Connecting with an Old Partner in a New Way
Ibrutinib Treatment of CLL: The Cancer Fights Back
Mind the IQGAP Cancer Cell
Volume 12, Issue 6, Pages (December 2007)
Kidney Cancer: Now Available in a New Flavor
Anthony N. Imbalzano, Stephen N. Jones  Cancer Cell 
The Ups and Downs of Src Regulation: Tumor Suppression by Cbp
Turning Reciprocal Feedback Regulation into Combination Therapy
Robert Morey, Louise C. Laurent  Cell Stem Cell 
Skp2, the FoxO1 hunter Cancer Cell
Presentation transcript:

Wild-Type RAS: Keeping Mutant RAS in CHK Theonie Anastassiadis, Eric J. Brown  Cancer Cell  Volume 25, Issue 2, Pages 137-138 (February 2014) DOI: 10.1016/j.ccr.2014.01.029 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 Regulation of the DNA Damage Response by Wild-Type RAS in Mutant KRAS Cells WT RAS antagonizes mutant KRAS signaling, thereby limiting the inhibitory phosphorylation of CHK1 at S280 from MAPK-RSK and PI3K-AKT signaling. Uninhibited pools of CHK1 afford an active DNA damage checkpoint response and some degree of genome maintenance. Suppressing WT RAS hyperactivates mutant KRAS signaling, which increases inhibitory phosphorylation of CHK1 at S280. CHK1 inhibition dampens the checkpoint and increases genomic instability. Cancer Cell 2014 25, 137-138DOI: (10.1016/j.ccr.2014.01.029) Copyright © 2014 Elsevier Inc. Terms and Conditions